Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib

First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis

(2016) Taimur Sher et al.   BLOOD

What is new in diagnosis and management of light chain amyloidosis?

(2016) G. Palladini et al.   BLOOD

Systemic amyloidosis

(2016) Ashutosh D Wechalekar et al.   LANCET

A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma

(2016) A Larocca et al.   LEUKEMIA

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

(2016) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies

(2015) Efstathios Kastritis et al.   AMERICAN JOURNAL OF HEMATOLOGY

A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis

(2015) G. Palladini et al.   BLOOD

A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis

(2015) Maria T. Cibeira et al.   BRITISH JOURNAL OF HAEMATOLOGY

Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens

(2015) Ruben Niesvizky et al.   JOURNAL OF CLINICAL ONCOLOGY

Translocation t(11;14) Is Associated With Adverse Outcome in Patients With Newly Diagnosed AL Amyloidosis When Treated With Bortezomib-Based Regimens

(2015) Tilmann Bochtler et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment of Immunoglobulin Light Chain Amyloidosis

(2015) Angela Dispenzieri et al.   MAYO CLINIC PROCEEDINGS

A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis

(2014) G. Palladini et al.   BLOOD

Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case–control study on 174 patients

(2014) G Palladini et al.   LEUKEMIA

A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis

(2014) C P Venner et al.   LEUKEMIA

A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision?

(2013) N. Leung et al.   HAEMATOLOGICA

Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach

(2013) G. Palladini et al.   HAEMATOLOGICA

Coexistent Multiple Myeloma or Increased Bone Marrow Plasma Cells Define Equally High-Risk Populations in Patients With Immunoglobulin Light Chain Amyloidosis

(2013) Taxiarchis V. Kourelis et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunoglobulin light chain amyloidosis

(2013) Giampaolo Merlini et al.   Expert Review of Hematology

Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis

(2012) J. R. Mikhael et al.   BLOOD

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma

(2012) S. Kumar et al.   BLOOD

A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis

(2012) E. Kastritis et al.   BLOOD

Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial

(2012) S. K. Kumar et al.   BLOOD

New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes

(2012) Giovanni Palladini et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study

(2011) D. E. Reece et al.   BLOOD

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation

(2011) M. Cavo et al.   BLOOD

Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis

(2010) Efstathios Kastritis et al.   JOURNAL OF CLINICAL ONCOLOGY